Company profile

NUPLAZID® (pimavanserin)

Learn about NUPLAZID®, a treatment option for hallucinations and delusions associated with Parkinson's disease psychosis. See Important Safety Information and Full Prescribing Information, including Boxed WARNING.

Profile another company Explore B2B directory

AI-verified profile

Location

San Diego, CA

Pricing

Public pricing page

AI Classification

HealthcarePharma/Biotech

Acadia Pharmaceuticals markets NUPLAZID® (pimavanserin), the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. This HCP-facing website supports US healthcare professionals with clinical efficacy data, safety information, and patient enrollment via the Acadia Connect program.

No deep intelligence yet

Run a full profile to see buying signals, account scoring, pain signals, and recommended contacts for NUPLAZID® (pimavanserin).

Run Full Profile

Competitors

steadiwear.com Traffic Comparison

NUPLAZID® (pimavanserin) is profiled by Kustiq, an AI company intelligence platform for B2B teams. NUPLAZID® (pimavanserin) is one of 7 pharma / biotech companies in our Healthcare directory.

How Kustiq built this profile

Hybrid pipeline: deterministic verification + Claude reasoning

Live web rendering via Browserless headless Chrome, not a stale cached scrape.
Search intelligence via Serper API across {company site, LinkedIn, press, GitHub}.
Claude Sonnet 4.6 classifies vertical, segment, and growth signals; never used for facts.
12-factor churn engine produces a deterministic risk score with zero LLM calls at scoring time.
SMTP RCPT TO handshake verifies every contact at delivery time on full profiles (paid plan).

Read the full methodology in our LLM-readable reference or compare against the deterministic-vs-AI framework.

Part of 3,020 AI-profiled B2B companies. Browse the full directory